NxStage Medical, Inc. Analyst Rating Update - American Trade Journal PDF Print

NxStage Medical, Inc. (NASDAQ:NXTM) has received a buy rating for the short term, according to the latest rank of 2 from research firm, Zacks. The company received an average rating of 2 from 6 analysts. 1 analyst have rated it as strong sell. 4 have rated it as a strong buy. 1 analysts have rated the company at hold.

Many analysts have commented on the company rating. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM). Investors must note that the brokerage house has a Buy rating on the shares of the company. The Equity Firm raises its price target from $24 per share to $27 per share. The rating by the firm was issued on February 27, 2015. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards $21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $15 per share. The higher price estimate target is at $24 according to the Analysts. NxStage Medical, Inc. (NASDAQ:NXTM) rose 0.49% or 0.09 points on Monday and made its way into the gainers of the day. After trading began at $18.15 the stock was seen hitting $18.43 as a peak level and $18.01 as the lowest level. The stock ended up at $18.36. The daily volume was measured at 569,733 shares. The 52-week high of the share price is $19.63 and the 52-week low is $11.5. The company has a market cap of $1,165 million. Shares of Nxstage Medical, Inc. rose by 2.63% in the last five trading days and 29.2% for the last 4 weeks. Nxstage Medical, Inc. is up 11.88% in the last 3-month period. Year-to-Date the stock performance stands at 2.4%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.